Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease
Document Type
Article
Abstract
As part of a safety and tolerability study, a 65-year-old man with Parkinson's disease (PD) received monthly intracerebroventricular injections of glial-derived neurotrophic factor (GDNF). His parkinsonism continued to worsen following intracerebroventricular GDNF treatment. Side effects included nausea, loss of appetite, tingling, L'hermitte's sign, intermittent hallucinations, depression, and inappropriate sexual conduct. There was no evidence of significant regeneration of nigrostriatal neurons or intraparenchymal diffusion of the intracerebroventricular GDNF to relevant brain regions. Alternative GDNF delivery systems should be explored.
Publication Date
9-13-1999
Publication Title
Annals of Neurology
ISSN
03645134
Volume
46
Issue
3
First Page
419
Last Page
424
PubMed ID
10482276
Digital Object Identifier (DOI)
10.1002/1531-8249(199909)46:3<419::AID-ANA21>3.0.CO;2-Q
Recommended Citation
Kordower, Jeffrey H.; Palfi, Stephane; Chen, Er Yun; Ma, Shuang Y.; Sendera, Timothy; Cochran, Elizabeth J.; Mufson, Elliott J.; Penn, Richard; Goetz, Christopher G.; and Comella, Cynthia D., "Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease" (1999). Translational Neuroscience. 1755.
https://scholar.barrowneuro.org/neurobiology/1755